Tuesday, November 17, 2026

Enamine and SyntheticGestalt to develop AI-based models to facilitate drug discovery!

SyntheticGestalt and Enamine will work on developing pre-training and generative AI models to discover synthesizable and drug-like candidate compounds using the 38 billion compounds in the REAL database as a training data set!

Collaboration to develop a series of AI models for AI drug discovery

SyntheticGestalt K.K. (Tokyo, Japan, CEO Koki Shimada), a research and development company specializing in AI development in the life sciences, and Enamine Ltd ( (Khiwo, Ukraine, CEO Andrey Tolmachov), a global provider of building block compounds, screening compounds, and integrated drug discovery services, announced today the start of a collaboration to develop a series of AI models to enable AI drug discovery.

The model will be used for SyntheticGestalt's services to academia and pharmaceutical companies, as well as for the company's research and development activities. The service will be used for SyntheticGestalt's services to academia and pharmaceutical companies and for the company's R&D activities.

Enamine is the largest database of on-demand compounds and provides access to the Enamine REAL database, which contains information on 38 billion compounds.
SyntheticGestalt is adding the Enamine REAL database to its Drug Discovery service. Enamine synthesizes proposed compounds in as little as 3-4 weeks and provides high-quality pharmacological in vitro profiling data through in-house testing. Enamine synthesizes proposed compounds in as little as 3-4 weeks and provides high quality pharmacological in vitro profiling data through in-house testing, helping to streamline and shorten the drug discovery cycle.

In addition, SyntheticGestalt will use the data provided by Enamine to enhance its pre-learning model. The model, which is expected to be the world's largest based on the 3D structure of a compound, will be used to improve the predictive accuracy of the company's machine learning models.
The model will also be proposed for collaborative research for other pharmaceutical companies. Details of the model and its performance will be presented at NVIDIA's annual NVIDIA GTC Japan AI Day event in March 2024.

Iaroslava Kos, Director of Business Development at Enamine, comments

The potential of AI/ML-assisted computer-aided design in the discovery of new drugs cannot be underestimated. Finding new active compounds by synthesizing just a handful of novel compounds is fantastic. We are pleased to enter into this collaboration with SyntheticGestalt and offer the talents and expertise of our scientists to help realize our mutual goals. We look forward to working together on our long-held dream of a cure."

Comments from Yukiteru Shimada, CEO of SyntheticGestalt

The application of machine learning in drug discovery research has long suffered from the problem of high performance on training data but low performance in real-world usage scenarios. The Enamine REAL database is ideal for our efforts because it is the largest and most trusted set of on-demand compounds on the market. We believe that just as large-scale pre-training has revolutionized large-scale language models (LLMs), we can enable a giant leap forward in AI drug discovery with the world's largest pre-training model developed in-house."

About SyntheticGestalt

SyntheticGestalt is an artificial intelligence research and development company specializing in the application of AI to drug discovery and other life science fields. Utilizing its proprietary artificial intelligence technology, SyntheticGestalt conducts research and development focused on the discovery of useful substances.
The AI platform used in this study is cloud-based, has a scalable structure, and can make predictions on large libraries, allowing prediction of physicochemical properties, ADME/ Tox properties, enzyme functions, etc.
SyntheticGestalt welcomes open innovation through collaboration with public institutions and private companies.

name of companySyntheticGestalt Corporation
EstablishmentDecember 2018
Location1-6 La Keyaki, Naito-cho, Shinjuku-ku, Tokyo
representativeKouki Shimada
uniform resouce locatorhttps://syntheticgestalt.com/

About SyntheticGestalt Drug Discovery Services

SyntheticGestalt offers a web service that proposes solutions to ADME/Tox and physicochemical property problems for Hit ~ Lead compounds based on proprietary machine learning models. https://drugdiscovery.syntheticgestalt.com/

About Enamine

Enamine is a science-driven, integrated drug discovery contract research organization with unique partnering opportunities in the discovery of new compound space. The company combines access to in-house produced screening compounds (4 million compounds in stock) and compound building blocks (300,000 compounds in stock) with a comprehensive platform that includes integrated drug discovery services to advance and accelerate drug discovery efforts.

name of companyEnamine Ltd.
Establishment1991
Location7 Deer Park Dr
Monmouth Junction, NJ, 08852, US
representativeCEO Andrey Tolmachov
Business OverviewChemical Manufacturing
uniform resouce locatorhttps://enamine.net

About Enamine REAL Database

The EnamineREAL® database (REadily AccesibLe) is a collection of over 38 billion molecules that can be synthesized and delivered by Enamine extremely quickly (3-4 weeks), highly feasible (>80%), and inexpensive. REAL compounds are synthesized using 167 different synthesized by parallel chemistry utilizing 137,000 compound building blocks via protocols and are the basis for Enamine's approach to designing on-demand compounds with maximum success rates.

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。